

• **Name:** Byoung (Brian) Ryu

• **Current Position:** Senior Vice President, Umoja Biopharma, Seattle WA

• **Country:** USA

• **Educational Background:**

- BS, Konkuk University, Korea (1994)
- MS, Konkuk University, Korea (1996)
- PhD, University of Tennessee, USA (2003)

• **Professional Experience:**

- Director, Vector Core, Seattle Children's Research Institute, USA (2008 - 2010)
- Principal Scientist, bluebird bio, USA (2010 - 2015)
- Associate Professor/Director, St. Jude Children's Research Hospital (2015 - 2019)
- VP, Lyell Immunopharma (2019 – 2020)
- SVP, Umoja Biopharma (2020 – Present)

• **Professional Organizations:**

- American Society of Gene and Cell Therapy
- American Society of Hematology

• **Main Scientific Publications:**

- Uchida N, Ferrara F..... Ryu B, Tisdale JF (2021). Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor. *Sci Transl Med* (in press).

- Seymour BJ,....Ryu BY, Khan IF, Adair JE, Rawlings DJ (2021) Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector. *Mol Ther Methods Clin Dev*. 2021 Jan 20;20:635-651.

- Jang Y, Kim YS, Wielgosz MM, Ferrara F, Ma Z, Condori J, Palmer LE, Zhao X, Kang G, Rawlings DJ, Zhou S, Ryu BY (2020). Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy. *Gene Ther*. 27(12):545-556

- Riberdy J, Zhou S, Zheng F, Kim YI, Moore J, Vaidya A, Throm RE, Sykes A, Sahr N, Bonifant C, Ryu B, Gottschalk S, Velasquez P (2020). The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing. *Mol Ther Methods Clin Dev* 18:571-581

- Bauler M, Roberts JK, Wu CC, Fan B, Ferrara F, Yip BH, Diao S, Kim YI, Moore J, Zhou S, Wielgosz MM, Ryu B, Throm RE (2019). Production of lentiviral vectors using suspension cells grown in serum-free media. *Mol Ther Methods Clin Dev*. 17:58-68.

- Kim YS, Wielgosz M, Ryu B (2019). The engraftment of lentiviral vector-transduced human CD34+ cells into humanized mice. *Methods Mol Biol*. 2005:91-100.